USA News Group News
Commentary
Issued on behalf of Avant Technologies
Inc.
VANCOUVER, BC, May 13, 2025
/PRNewswire/ -- USA News
Group News Commentary – In a clear sign of
growing confidence in artificial intelligence (AI) for healthcare,
the U.S. Food and Drug Administration (FDA) has now fully
adopted internal AI use, following the successful trial of a
generative AI tool designed to streamline scientific review. The
system, which helps FDA experts reduce time spent on
repetitive tasks, marks a pivotal shift toward automation within
regulatory processes. Analysts say this shift further confirms AI's
growing role in the future of medicine, with
MarketsandMarkets projecting the AI healthcare sector to
climb at a 38.6% CAGR, reaching over US$110.61 billion by 2030. As the FDA
leans into AI for its own operations, attention is turning to
public companies advancing their own healthcare AI platforms—among
them Avant Technologies, Inc. (OTCQB: AVAI), RadNet,
Inc. (NASDAQ: RDNT), iCad, Inc. (NASDAQ: ICAD),
Microsoft Corporation (NASDAQ: MSFT), and HEALWELL AI
Inc. (TSX: AIDX) (OTCQX: HWAIF).
Major funding continues to pour into the AI healthcare sector,
highlighted by Persivia's recent $107
million raise to scale its AI-powered platform. Looking
ahead, analysts project that by 2035, artificial intelligence could
inject an additional $461 billion
into a global healthcare system already set to exceed $2.26 trillion.
Avant Technologies, Inc. (OTCQB: AVAI) is deepening its
footprint in AI-driven healthcare through a proposed acquisition of
its joint venture partner Ainnova Tech. The two companies,
already working together under Ai-nova Acquisition Corp.
(AAC), have entered formal negotiations to merge into a single
entity ahead of their scheduled FDA pre-submission meeting
this July. The move is expected to streamline regulatory
coordination, simplify clinical trial execution, and enhance
commercial alignment as they prepare for U.S. market entry.
"We believe bringing the two companies together will offer
tremendous value for shareholders," said Vinicio Vargas, CEO at Ainnova and a
member of the Board of Directors of Ai-nova Acquisition
Corp. "It will simplify the process of advancing our technology
to market, and it will deliver value to our customers and partners
as we promote our technology portfolio globally."
Operating through AAC, the companies hold global
rights to Vision AI, a non-invasive clinical screening platform
that integrates retinal imaging, vital sign capture, and
proprietary algorithms to detect early signs of diabetic
retinopathy, cardiovascular disease, liver fibrosis, kidney
disease, and type 2 diabetes. According to NIH-cited
research, AI tools like Vision AI have demonstrated over 90%
sensitivity in detecting conditions before symptoms emerge.
"This milestone reflects our two-tiered strategy, rapid
deployment in low-regulation markets where Vision AI operates as a
screening tool, and simultaneous progress toward FDA
clearance for the U.S. market," said Vargas. "Entering the U.S.
will unlock significant commercial potential, and early engagement
with regulators ensures we do so with speed, credibility, and a
validated product."
While many early-stage healthcare AI companies remain
pre-commercial, Vision AI is already active in pilot programs
across Latin America, including
Chile, Mexico, and Brazil. These deployments are generating
real-world data and validating the platform in everyday clinical
settings.
To support the next phase of growth, AAC recently
integrated four new diagnostic algorithms trained on more than 2.3
million clinical cases, boosting the platform's utility across a
broader range of chronic conditions. With momentum building across
regulatory, commercial, and clinical fronts, Avant appears
well-positioned for the next leg of its journey.
CONTINUED… Read this and more news for Avant Technologies
Inc.
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
RadNet, Inc. (NASDAQ: RDNT) and iCad, Inc.
(NASDAQ: ICAD) have announced a definitive merger agreement,
combining two leaders in AI-powered breast cancer detection. The
all-stock transaction, valued at approximately $103 million, will bring iCAD's global
install base of 1,500+ healthcare providers and its ProFound Breast
Health Suite into RadNet's DeepHealth portfolio.
"iCAD's ProFound Breast Health Suite and RadNet's
DeepHealth AI-powered breast screening solutions, together, have
the power to materially expand and improve patient diagnosis and
outcomes on a global basis through further enabling accuracy and
early-detection," said Dr. Howard
Berger, President and CEO of RadNet. "This business
combination is expected to accelerate our global leadership and
commitment to AI-powered breast cancer screening, and positions us
to further advance population health."
The integration is expected to accelerate innovation in early
detection and workflow tools for radiologists, bolstering
RadNet's position in AI-driven cancer screening. With
regulatory approvals pending, the merger is projected to close by
Q3 2025.
"As we join forces with RadNet to create a broad offering
of AI-driven solutions, we have the opportunity to redefine how
breast cancer and other diseases are detected and treated," said
Dana Brown, President and CEO of
iCAD. "Together, we will work to expand access to
cutting-edge tools, accelerate innovation and advance our product
roadmaps, empowering radiologists with more precise, efficient and
scalable solutions that should ultimately improve patient care and
outcomes."
As iCAD moves forward with RadNet, it is also
deepening its standalone capabilities through a new collaboration
with Microsoft Corporation (NASDAQ: MSFT), as the ProFound
Breast Health Suite will now be available through
Microsoft's Precision Imaging Network, integrated directly
with PowerScribe—used by most U.S. radiologists for AI-driven
reporting. This partnership brings iCAD's AI-powered
mammography solutions to over 17,000 healthcare facilities,
enabling real-time insights, streamlined workflows, and broader
access to early breast cancer detection.
"With the integration of iCAD's ProFound suite of breast
health offerings with our Precision Imaging Network and PowerScribe
solutions, we will help provide radiologists and patients with more
accurate, actionable breast health insights, while streamlining
mammography screening workflow, driving clinical and operational
value at scale." said Vikram
Chhabra, General Manager, Diagnostic Solutions at
Microsoft.
A recent Microsoft blog post highlighted how AI is
already transforming healthcare by reducing clinician burnout,
streamlining diagnostics, and personalizing treatments.
Tools like Dragon Copilot are allowing doctors to spend more
time with patients while automating documentation tasks. In
imaging, Microsoft's multimodal AI models enable faster,
more accurate disease detection and offer new capabilities like
conversing with scans using natural language. These advancements,
built on platforms like Azure and Microsoft Fabric, are empowering
both providers and developers to deliver smarter, data-driven care
at scale.
HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) recently
acquired Orion Health in a transformative deal that
significantly expands its global reach and public sector presence.
With Orion's platform supporting over 150 million patient
lives across 11 countries, the acquisition strengthens
HEALWELL's position in AI-powered healthcare data
interoperability.
"The acquisition of Orion Health represents a transformative
milestone for the Company, bringing large enterprise customers,
recurring revenues, strong operating margins and free cashflow
conversion to HEALWELL while providing a significant new channel
for the distribution of our best-in-class AI products," said Dr.
Alexander Dobranowski, CEO of
HEALWELL. "In addition, the acquisition strengthens our
position in the public sector, enabling us to deepen our reach with
government partners, thanks to Orion Health's strong,
long-standing relationships."
The combined entity is now positioned as a global leader in
delivering actionable insights through AI, unlocking new revenue
streams and accelerating innovation across population health.
Source:
https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Avant Technologies Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares Avant Technologies Inc., and may liquidate their shares
which could have a negative effect on the price of the stock. This
compensation constitutes a conflict of interest as to our ability
to remain objective in our communication regarding the profiled
company. Because of this conflict, individuals are strongly
encouraged to not use this publication as the basis for any
investment decision. The owner/operator of MIQ own shares of Avant
Technologies Inc. which were purchased in the open market. MIQ
reserves the right to buy and sell, and will buy and sell shares of
Avant Technologies Inc. at any time thereafter without any further
notice. We also expect further compensation as an ongoing digital
media effort to increase visibility for the company, no further
notice will be given, but let this disclaimer serve as notice that
all material disseminated by MIQ has been approved by the above
mentioned company; this is a paid advertisement, and we own shares
of the mentioned company that we will sell, and we also reserve the
right to buy shares of the company in the open market, or through
other investment vehicles. While all information is believed to be
reliable, it is not guaranteed by us to be accurate. Individuals
should assume that all information contained in our newsletter is
not trustworthy unless verified by their own independent research.
Also, because events and circumstances frequently do not occur as
expected, there will likely be differences between any predictions
and actual results. Always consult a licensed investment
professional before making any investment decision. Be extremely
careful, investing in securities carries a high degree of risk; you
may likely lose some or all of the investment.
Logo :
https://mma.prnewswire.com/media/2603685/5316492/USA_News_Group_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/behind-the-fdas-ai-push-a-growing-class-of-public-healthcare-innovators-302454103.html
SOURCE USA News Group
